Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic.
COVID-19
SARS-CoV2
diffuse glioma
outcome
prognosis
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Little is known about diffuse glioma patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). We performed a descriptive and retrospective analysis of 41 diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the COVID-19 pandemic. Confusion with or without fever was the most common neurological symptom (32%) supporting SARS-CoV2 testing in glioma patients with acute and unexplained confusion. Sixteen patients (39%) died after a median delay of 13 days. While multiple clinical, biological, and pathological features, COVID-19- or diffuse glioma-related, at hospital admission appeared to have a pejorative prognostic impact, none was significantly associated with death. Oncological treatments were interrupted at COVID-19 diagnosis and re-initiated with a median delay of 30 days after the end of COVID-19 symptoms. Interestingly, our retrospective study describes for the first time the characteristics of a cohort of diffuse glioma patients with symptomatic COVID-19. Diffuse glioma patients with poorly symptomatic COVID-19 did not come to the attention of physicians and were not enrolled in the study skewing the denominator for prognostic analysis. Further studies are warranted to specify prognosis of overall population of diffuse glioma patients with COVID-19, including asymptomatic patients, and interactions of prognostic factors of both COVID-19 and diffuse gliomas.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about diffuse glioma patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
METHODS
METHODS
We performed a descriptive and retrospective analysis of 41 diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the COVID-19 pandemic.
RESULTS
RESULTS
Confusion with or without fever was the most common neurological symptom (32%) supporting SARS-CoV2 testing in glioma patients with acute and unexplained confusion. Sixteen patients (39%) died after a median delay of 13 days. While multiple clinical, biological, and pathological features, COVID-19- or diffuse glioma-related, at hospital admission appeared to have a pejorative prognostic impact, none was significantly associated with death. Oncological treatments were interrupted at COVID-19 diagnosis and re-initiated with a median delay of 30 days after the end of COVID-19 symptoms.
CONCLUSIONS
CONCLUSIONS
Interestingly, our retrospective study describes for the first time the characteristics of a cohort of diffuse glioma patients with symptomatic COVID-19. Diffuse glioma patients with poorly symptomatic COVID-19 did not come to the attention of physicians and were not enrolled in the study skewing the denominator for prognostic analysis. Further studies are warranted to specify prognosis of overall population of diffuse glioma patients with COVID-19, including asymptomatic patients, and interactions of prognostic factors of both COVID-19 and diffuse gliomas.
Identifiants
pubmed: 34396128
doi: 10.1093/noajnl/vdab078
pii: vdab078
pmc: PMC8360904
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab078Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x
pubmed: 26611557
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Aging Male. 2020 Dec;23(5):1416-1424
pubmed: 32508193
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1011-1019
pubmed: 32291542
Am J Emerg Med. 2020 Sep;38(9):1715-1721
pubmed: 32731141
Eur J Cancer. 2020 Jun;132:5-7
pubmed: 32302754
Eur J Cancer. 2020 Sep;136:99-106
pubmed: 32659475
JAMA Netw Open. 2020 Nov 2;3(11):e2029540
pubmed: 33211114
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cleve Clin J Med. 2020 Nov 23;87(12):729-734
pubmed: 32847818
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
J Neurol Sci. 2020 Jun 15;413:116832
pubmed: 32299017
Am J Clin Oncol. 2020 Jun;43(6):452-455
pubmed: 32304435
J Clin Neurosci. 2020 Jul;77:13-16
pubmed: 32417124
Arch Gerontol Geriatr. 2021 Jul-Aug;95:104388
pubmed: 33713880